These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20085455)

  • 1. Multiplexed random peptide library and phospho-specific antibodies facilitate human polo-like kinase 1 inhibitor screen.
    Tanaka K; Koresawa M; Iida M; Fukasawa K; Stec E; Cassaday J; Chase P; Rickert K; Hodder P; Takagi T; Komatani H
    Assay Drug Dev Technol; 2010 Feb; 8(1):47-62. PubMed ID: 20085455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a High-Throughput Assay for Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1 Based on Time-Resolved Fluorescence Energy Transfer.
    Kim TG; Lee JH; Lee MY; Kim KU; Lee JH; Park CH; Lee BH; Oh KS
    Biol Pharm Bull; 2017; 40(9):1454-1462. PubMed ID: 28867728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and implementation of a miniaturized high-throughput time-resolved fluorescence energy transfer assay to identify small molecule inhibitors of polo-like kinase 1.
    Sharlow ER; Leimgruber S; Shun TY; Lazo JS
    Assay Drug Dev Technol; 2007 Dec; 5(6):723-35. PubMed ID: 18181689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
    Reindl W; Strebhardt K; Berg T
    Anal Biochem; 2008 Dec; 383(2):205-9. PubMed ID: 18793607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
    Johnson EF; Stewart KD; Woods KW; Giranda VL; Luo Y
    Biochemistry; 2007 Aug; 46(33):9551-63. PubMed ID: 17655330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Analysis of a FRET-based PLK1 Kinase Assay to Identify PLK1 inhibitors for Chemotherapy.
    Shin SB; Woo SU; Lee YJ; Yim H
    Anticancer Res; 2017 Mar; 37(3):1177-1183. PubMed ID: 28314279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach.
    Kumar M; Pydi SP; Sharma S; Singh TP; Kaur P
    J Mol Graph Model; 2014 Jun; 51():104-12. PubMed ID: 24879322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors.
    Yun T; Qin T; Liu Y; Lai L
    Eur J Med Chem; 2016 Nov; 124():229-236. PubMed ID: 27592392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
    Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
    Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1.
    Chen Y; Li Z; Liu Y; Lin T; Sun H; Yang D; Jiang C
    Bioorg Chem; 2018 Dec; 81():278-288. PubMed ID: 30170276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor as an Anticancer Drug Candidate through Structure-Based Design.
    Zhou Y; Yan F; Huo X; Niu MM
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31795214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced cellular uptake of a TAT-conjugated peptide inhibitor targeting the polo-box domain of polo-like kinase 1.
    Kim SM; Chae MK; Lee C; Yim MS; Bang JK; Ryu EK
    Amino Acids; 2014 Nov; 46(11):2595-603. PubMed ID: 25151148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate.
    Nakajima H; Toyoshima-Morimoto F; Taniguchi E; Nishida E
    J Biol Chem; 2003 Jul; 278(28):25277-80. PubMed ID: 12738781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.
    Hermanson SB; Carlson CB; Riddle SM; Zhao J; Vogel KW; Nichols RJ; Bi K
    PLoS One; 2012; 7(8):e43580. PubMed ID: 22952710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel anti-tumor inhibitor identified by virtual screen with PLK1 structure and zebrafish assay.
    Lu J; Xin S; Meng H; Veldman M; Schoenfeld D; Che C; Yan R; Zhong H; Li S; Lin S
    PLoS One; 2013; 8(4):e53317. PubMed ID: 23658603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands.
    Elling RA; Fucini RV; Romanowski MJ
    Acta Crystallogr D Biol Crystallogr; 2008 Sep; 64(Pt 9):909-18. PubMed ID: 18703838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay.
    Normandin K; Lavallée JF; Futter M; Beautrait A; Duchaine J; Guiral S; Marinier A; Archambault V
    Sci Rep; 2016 Nov; 5():37581. PubMed ID: 27874094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors.
    Liu M; Poulose S; Schuman E; Zaitsev AD; Dobson B; Auerbach K; Seyb K; Cuny GD; Glicksman MA; Stein RL; Yue Z
    Anal Biochem; 2010 Sep; 404(2):186-92. PubMed ID: 20566370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds.
    Raab M; Sanhaji M; Pietsch L; Béquignon I; Herbrand AK; Süß E; Gande SL; Caspar B; Kudlinzki D; Saxena K; Sreeramulu S; Schwalbe H; Strebhardt K; Biondi RM
    ACS Chem Biol; 2018 Aug; 13(8):1921-1931. PubMed ID: 29927572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure of the catalytic domain of human polo-like kinase 1.
    Kothe M; Kohls D; Low S; Coli R; Cheng AC; Jacques SL; Johnson TL; Lewis C; Loh C; Nonomiya J; Sheils AL; Verdries KA; Wynn TA; Kuhn C; Ding YH
    Biochemistry; 2007 May; 46(20):5960-71. PubMed ID: 17461553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.